Cytokinetics, Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTK research report →
Companywww.cytokinetics.com
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.
- CEO
- Robert I. Blum
- IPO
- 2004
- Employees
- 498
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $9.80B
- P/E
- -11.70
- P/S
- 92.63
- P/B
- -11.75
- EV/EBITDA
- -14.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.34%
- Op Margin
- -605.06%
- Net Margin
- -784.02%
- ROE
- 139.66%
- ROIC
- -56.16%
Growth & Income
- Revenue
- $88.04M · 376.56%
- Net Income
- $-784,955,000 · -33.15%
- EPS
- $-6.54 · -24.33%
- Op Income
- $-612,258,000
- FCF YoY
- -33.77%
Performance & Tape
- 52W High
- $80.20
- 52W Low
- $29.81
- 50D MA
- $66.51
- 200D MA
- $59.91
- Beta
- 0.38
- Avg Volume
- 2.51M
Get TickerSpark's AI analysis on CYTK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Blum Robert I | sell | 7,500 |
| May 5, 26 | Malik Fady Ibraham | other | 3,500 |
| May 5, 26 | Malik Fady Ibraham | sell | 3,500 |
| May 5, 26 | Malik Fady Ibraham | other | 3,500 |
| May 5, 26 | WIERENGA WENDELL | other | 4,032 |
| May 5, 26 | WIERENGA WENDELL | sell | 4,032 |
| May 5, 26 | WIERENGA WENDELL | other | 4,032 |
| May 5, 26 | Lee Sung | sell | 23,906 |
| May 5, 26 | HENDERSON JOHN T | other | 20,000 |
| May 5, 26 | HENDERSON JOHN T | sell | 20,000 |
Our CYTK Coverage
We haven't published any research on CYTK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYTK Report →